
Biotechs emerging from stealth take aim at pharma’s prime targets
If the recent crop of companies emerging from stealth is any indication, innovators are doubling down on opportunities to join the juggernaut weight loss market while exploring fresh opportunities in immuno-oncology and pain management. Investors appear …